Effect of ABO blood group on the collagen‐binding assay for von Willebrand factor

Haley, Erin B.; Babar, Nadiya; Ritter, Cory; Downes, Katharine A.; Green, Deana; Shurin, Susan B.; Sarode, Ravindra

doi:10.1002/ajh.10238

Cited by 11 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is particularly relevant in view of the association described between vWF proteolysis by ADAMTS13 and the ABO group. 27 In support of previous findings, [24][25][26] we also found a significant difference between levels of plasma FVIII and vWF as detected in samples from the O blood group vs samples from non-O blood groups ( Figure 3A). We also determined a differing tendency in terms of the absolute loss of plasma FVIII:C and vWF following cold storage ( Figure 3C).…”

Section: Discussionsupporting

confidence: 91%

“…The fall in the plasma FVIII:C level also is likely to be due to the loss of vWF, although a more direct effect on FVIII:C cannot be discounted. Because the ABO blood group system has been described as a determinant of plasma FVIII and vWF levels, [24][25][26] we also assessed the influence of the ABO system on the cold-activation phenomenon. This is particularly relevant in view of the association described between vWF proteolysis by ADAMTS13 and the ABO group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing

Favaloro¹,

Soltani²,

McDonald³

2004

Am J Clin Pathol

View full text Add to dashboard Cite

To assess the potential for misdiagnosis of von Willebrand disorder (vWD) and hemophilia A while following current National Committee for Clinical Laboratory Standards (NCCLS) guidelines and consequent to a poorly recognized cold-activation phenomenon, we processed 39 normal citrate-anticoagulated samples by standard procedures (reference) or stored at low (approximately 4 degrees C) or ambient (approximately 22 degrees C) temperature for 3.5 hours before centrifugation and processing. Samples were tested in parallel for several hemostasis factors, including von Willebrand factor (vWF). Similar results were obtained for all samples for factors II, V, VII, IX, X, XI, and XII. For factor VIII (FVIII) and vWF, only samples stored at ambient temperature had results comparable to reference sample results. In most cases, low temperature storage led to much lower results. Taking the lower reference limit as 50%, most would have been defined as "abnormal," and a misdiagnosis of vWD or hemophilia A could easily arise. ABO classification and age were associated with FVIII and vWF levels, but neither was associated conclusively with relative loss of plasma FVIII coagulant and vWF caused by the cold-activation phenomenon. We advise laboratories following current NCCLS guidelines not to store or transport whole blood samples for FVIII and vWF testing at 2 degrees C to 4 degrees C because of the risk of misdiagnosing vWD or hemophilia A. Storage and transport at ambient temperature seem acceptable and provide results comparable to freshly centrifuged samples.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing

Favaloro¹,

Soltani²,

McDonald³

2004

Am J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…Few reports have extensively evaluated VWF:CB in healthy individuals. Blood group has been shown to affect VWF:CB, with lower VWF:CB (commensurate with the decrease in VWF:Ag) in healthy controls who were blood group O as compared with non‐O [14,22]. Because both VWF:CB and VWF:Ag decrease in blood group O individuals, the ratio is not affected.…”

Section: Discussionmentioning

confidence: 99%

Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease

Flood

Gill

Christopherson

et al. 2012

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Summary Background Von Willebrand factor (VWF) plays a key role in coagulation by tethering platelets to injured subendothelium through binding sites for collagen and platelet GPIb. Collagen binding assays (VWF:CB), however, are not part of the routine workup for von Willebrand disease (VWD). Objectives This study presents data on collagen binding for healthy controls and VWD subjects to compare three different collagens. Patients/Methods VWF antigen (VWF:Ag), VWF ristocetin cofactor activity, and VWF:CB with types I, III, and VI collagen were examined for samples obtained from the Zimmerman Program. Results Mean VWF:CB in healthy controls was similar and highly correlated for types I, III, and VI collagen. The mean VWF:CB/VWF:Ag ratios for types I, III, and VI collagen were 1.31, 1.19, and 1.21 respectively. In type 1 VWD subjects, VWF:CB was similar to VWF:Ag with mean VWF:CB/VWF:Ag ratios for types I, III, and VI collagen of 1.32, 1.08, and 1.1 respectively. For type 2A and 2B subjects, VWF:CB was uniformly low, with mean ratios of 0.62 and 0.7 for type I collagen, 0.38 and 0.4 for type III collagen, and 0.5 and 0.47 for type VI collagen. Conclusions Normal ranges for type I, III, and VI collagen are correlated, but higher values were obtained with type I collagen as compared to types III and VI. The low VWF:CB in type 2A and 2B subjects suggests that VWF:CB may also supplement analysis of multimer distribution. However, these results reflect only one set of assay conditions per collagen type and therefore may not be generalizable to all collagen assays.

show abstract

“…48 Although the clinical significance of these data remains unclear, several studies performed on healthy controls have reported differential effects of ABO blood group on VWF functional assays (including VWF: RCo and VWF:collagen binding). 44,49,50 Conflicting conclusions have been reported from some of these studies that may relate in part to the different types of assay conditions used, together with differences in ethnic origins. A recent study has defined polymorphisms in the VWF A1 domain (in particular D1472H) that attenuate the ability of VWF to bind ristocetin.…”

Section: Abo Blood Group and Vwf Functional Activitymentioning

confidence: 99%

The relationship between ABO blood group, von Willebrand factor, and primary hemostasis

Ward

O’Sullivan

O’Donnell

2020

Blood

101

View full text Add to dashboard Cite

Numerous studies have reported significant associations between ABO blood group and risk for cardiovascular disease. These studies have consistently demonstrated that thrombotic risk is significantly reduced in blood group O individuals. Nevertheless, the biological mechanisms through which ABO influences hemostasis have remained poorly understood. Exciting recent data have provided novel insights into how these ABO effects are modulated, and highlighted that ABO group significantly influences platelet plug formation at sites of vascular injury (primary hemostasis). In particular, ABO affects multiple aspects of von Willebrand factor (VWF) biology. In keeping with their reduced thrombotic risk, plasma VWF levels are approximately 25% lower in normal group O compared to non-O individuals. In addition, blood group O VWF demonstrates enhanced susceptibility to ADAMTS13 proteolysis. Finally, preliminary findings suggest that the ability of group O VWF to interact with platelets may also be reduced. Although the molecular mechanisms underlying these ABO effects on VWF have not been fully elucidated, it seems likely that they are mediated in large part by ABO(H) carbohydrate structures carried on both the N- and O-linked glycans of VWF. Interestingly, ABO(H) determinants are also expressed on a number of different platelet surface glycoprotein receptors. Recent studies support the hypothesis that ABO group not only exerts major quantitative and qualitative effects on VWF, but also may affect specific aspects of platelet function. Given the huge morbidity and mortality associated with thrombotic disorders, defining the mechanisms underlying these ABO effects is not only of scientific interest, but also of direct clinical importance.

show abstract

Effect of ABO blood group on the collagen‐binding assay for von Willebrand factor

Cited by 11 publications

References 8 publications

Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing

Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing

Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease

The relationship between ABO blood group, von Willebrand factor, and primary hemostasis

Contact Info

Product

Resources

About